PINE BROOK, N.J., Feb. 13 /PRNewswire/ -- Elusys Therapeutics, Inc., a
developer of targeted anti-infective therapeutics, today announced that it
will be presenting new post exposure efficacy data on Anthim(TM), the
Company's anthrax therapeutic, at The 4th Annual American Society of
Microbiology Biodefense Research Conference.
The conference brings together top scientists conducting critical research
to defend against the growing threat of bioterrorism and decision makers
shaping the future biodefense research agenda. The conference takes place
February 15 - 18, 2006 at the Hyatt Regency Hotel in Washington, DC.
Leslie Casey, Ph.D., Executive Director, Preclinical Development &
Immunology of Elusys Therapeutics, will make a presentation (#69D Posterboard
50) entitled, "Intramuscular Administration of Anthim(TM), a High-Affinity
Anti-Protective Antigen MAb, Enhances Post-exposure Antibiotic Efficacy
against Lethal B. anthracis Spore Challenge," on Thursday, February 16, 2006
from 1:00 - 2:30 PM in the Columbia Ballroom.
About Anthim(TM)
Anthim is a high-affinity monoclonal antibody that targets the protective
antigen (PA) component of anthrax, blocking the bacteria's ability to form
deadly toxins. Anthim is being developed under The Food and Drug
Administration (FDA) Animal Rule, a regulatory process specifically designed
for the development of medical countermeasures to bioterror threats.
According to this rule, marketing approval of Anthim can be granted based on
efficacy in relevant animal models with only Phase I safety trials required in
humans. In Q4 2005, Elusys initiated a Phase I human safety study of Anthim
and the drug has been granted Fast Track status by the FDA. The Company has
initiated manufacturing scale-up to produce Anthim in commercial quantities in
preparation for a potential US Government purchase for the Strategic National
Stockpile.
For more information on Anthim(TM) please visit
http://www.elusys.com/product_development_anthim.php
For more information on the ASM Biodefense Conference please visit
http://www.asmbiodefense.org
About Elusys
Elusys is a privately-held biopharmaceutical company focused on the
development of targeted anti-infective therapeutics. Current venture
investors include Essex Woodlands Health Ventures LLC, Invesco Private
Capital, Crescendo Ventures, EagleAdvisors, and the Legg Mason Emerald Fund.
To date, the Company has been awarded $20M from the U.S. Government for the
development of novel therapeutics to combat bioterror agents. For more
information on Elusys please visit http://www.elusys.com.
SOURCE Elusys Therapeutics, Inc.
 back to top
Related links:
http://www.elusys.com
CONTACT:
Bryan Murphy of LaVoie Group, 781-596-0200
X-105, or bmurphy@lavoiegroup.com, for Elusys Therapeutics, Inc.
|
